Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$24.98 USD
+0.81 (3.35%)
Updated Aug 23, 2024 03:59 PM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Chugai Pharmaceutical Co, Ltd Unsponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5,247 | 3,874 | 4,295 | 3,559 | 3,064 |
Receivables | 2,274 | 3,960 | 3,240 | 2,382 | 1,671 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | 1,942 | 2,250 | 1,900 | 1,729 | 1,547 |
Other Current Assets | 239 | 207 | 244 | 179 | 155 |
Total Current Assets | 9,702 | 10,291 | 9,679 | 7,848 | 6,437 |
Net Property & Equipment | 2,911 | 2,890 | 3,083 | 2,719 | 2,351 |
Investments & Advances | NA | 14 | 22 | 27 | 27 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | 511 | 542 | 524 | 455 | 393 |
Intangibles | 141 | 194 | 200 | 224 | 217 |
Deposits & Other Assets | 381 | 379 | 373 | 263 | 228 |
Total Assets | 13,721 | 14,397 | 14,002 | 11,614 | 9,742 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 799 | 1,616 | 1,386 | 944 | 714 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | 290 | 759 | 785 | 594 | 378 |
Other Current Liabilities | 958 | 888 | 808 | 682 | 557 |
Total Current Liabilities | 2,046 | 3,263 | 2,980 | 2,219 | 1,649 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 63 | 80 | 96 | 108 | 151 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 70 | 87 | 116 | 75 | 85 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 2,179 | 3,429 | 3,191 | 2,402 | 1,885 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 520 | 564 | 666 | 688 | 672 |
Capital Surplus | 492 | 530 | 621 | 635 | 617 |
Retained Earnings | 10,570 | 9,959 | 9,592 | 7,981 | 6,643 |
Other Equity | -41 | -84 | -68 | -93 | -75 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 11,542 | 10,968 | 10,811 | 9,212 | 7,857 |
Total Liabilities & Shareholder's Equity | 13,721 | 14,397 | 14,002 | 11,614 | 9,742 |
Total Common Equity | 111,541 | 10,968 | 10,811 | 9,212 | 7,857 |
Shares Outstanding | 3,289.90 | 3,289.90 | NA | NA | NA |
Book Value Per Share | 33.90 | 3.33 | -0.11 | -0.09 | -0.08 |
Fiscal Year End for Chugai Pharmaceutical Co, Ltd Unsponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 5,247 | 4,269 | -99,999 |
Receivables | NA | NA | 2,274 | 2,188 | NA |
Notes Receivable | NA | NA | NA | NA | NA |
Inventories | NA | NA | 1,942 | 1,915 | NA |
Other Current Assets | NA | NA | 239 | 301 | NA |
Total Current Assets | NA | NA | 9,702 | 8,673 | NA |
Net Property & Equipment | NA | NA | 2,911 | 2,802 | NA |
Investments & Advances | NA | NA | NA | NA | NA |
Other Non-Current Assets | NA | NA | NA | NA | NA |
Deferred Charges | NA | NA | 511 | 486 | NA |
Intangibles | NA | NA | 141 | 138 | NA |
Deposits & Other Assets | NA | NA | 381 | 362 | NA |
Total Assets | NA | NA | 13,721 | 12,542 | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | NA |
Accounts Payable | NA | NA | 799 | 775 | NA |
Current Portion Long-Term Debt | NA | NA | NA | NA | NA |
Current Portion Capital Leases | NA | NA | NA | NA | NA |
Accrued Expenses | NA | NA | NA | NA | NA |
Income Taxes Payable | NA | NA | 290 | 81 | NA |
Other Current Liabilities | NA | NA | 958 | 966 | NA |
Total Current Liabilities | NA | NA | 2,046 | 1,822 | NA |
Mortgages | NA | NA | NA | NA | NA |
Deferred Taxes/Income | NA | NA | 63 | 55 | NA |
Convertible Debt | NA | NA | NA | NA | NA |
Long-Term Debt | NA | NA | NA | NA | NA |
Non-Current Capital Leases | NA | NA | NA | NA | NA |
Other Non-Current Liabilities | NA | 70 | 73 | NA | |
Minority Interest (Liabilities) | NA | NA | NA | NA | NA |
Total Liabilities | NA | NA | 2,179 | 1,950 | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | NA |
Common Stock (Par) | NA | NA | 520 | 505 | NA |
Capital Surplus | NA | NA | 492 | 478 | NA |
Retained Earnings | NA | NA | 10,570 | 9,630 | NA |
Other Equity | NA | NA | -41 | -21 | NA |
Treasury Stock | NA | NA | NA | NA | NA |
Total Shareholder's Equity | NA | NA | 11,542 | 10,591 | NA |
Total Liabilities & Shareholder's Equity | NA | NA | 13,721 | 12,542 | NA |
Total Common Equity | 0 | 0 | 111,541 | 110,590 | 0 |
Shares Outstanding | 3,289.90 | 3,289.90 | 3,289.90 | 3,289.90 | 3,289.90 |
Book Value Per Share | 0.00 | 0.00 | 33.90 | 33.62 | 0.00 |